Genmab — April 2020
-
-
Novartis AG (NVS) CEO on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4340622-novartis-ag-nvs-ceo-vasant-narasimhan-on-q1-2020-results-earnings-call-transcript?part=single
-
Sounds like Novartis will be very aggressive in maketing ofa in MS...
-
PharmiWeb.com – Thank you
After twenty-five years, PharmiWeb.com is closing. A note of thanks to the pharmaceutical industry community that built it.
(www.pharmiweb.com)
-
God morgen
-
Bergenbio + 119%
-
-
Ofatumumab abstracts at the (cancelled) 2020 American Academy of Neurology Annual Meeting via https://index.mirasmart.com/AAN2020/SearchResults.php?q=ofatumumab
-
You were in the wrong chat E L. “It is clear that early initiation of highly effective treatment for MS improves long-term outcomes, and there is great need for potent, safe, and convenient therapy that can be used to treat MS from the start,” professor Stephen L. Hauser, MD, director of the UCSF Weill Institute for Neurosciences, said in a statement. https://www.pharmacytimes.com/news/ofatumumab-demonstrates-efficacy-in-relapsing-multiple-sclerosis
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind